Merck's Allergopharma opens €42m biopharmaceutical plant

Allergopharma, a subsidiary of Germany’s Merck, has completed construction on its new €42 million biopharmaceutical facility and declared it open for business.

Work on the 6,000 square metre plant in Reinbek, near Hamburg, began in 2013, with Allergopharma stating that the new operation would aid its expansion into such as China. The company focuses on the development and production of immunotherapies for the treatment of allergies such as allergic rhinitis and allergic asthma.

Chief Operating Officer Simon Sturge stressed the significance of the new facility in a statement: ‘‘with this €42 million investment Merck is supporting the Reinbek site in order to expand the allergies business on a global scale. The new production building is part of this global expansion, and will support our growing business in the allergy marketplace."

CEO of Allergopharma Marco Linari added: "From a technology point of view, the new biopharmaceutical production is a quantum leap. It means an increase in supply safety for patients, a further improvement of product quality and future innovations towards improving therapy."